Publications by authors named "Matthieu Texier"

Claim this Profile
R
Reply to: "FOLFIRINOX for Locally Advanced Pancreatic Cancer: The Need for Individualized Strategies," "Conversion Chemotherapy for Locally Advanced Pancreatic Carcinoma: FOLFIRINOX or Gemcitabine?," and "Chemotherapy for Locally Advanced Pancreatic Cancer: The Dilemma of David Versus Goliath After NEOPAN".
Michel Ducreux, Matthieu Texier, Olivier Bouche

J Clin Oncol· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
PRODIGE 29-UCGI 26 (NEOPAN): A Phase III Randomized Trial Comparing Chemotherapy With FOLFIRINOX or Gemcitabine in Locally Advanced Pancreatic Carcinoma.
Michel Ducreux, Romain Desgrippes, Yves Rinaldi, Frédéric Di Fiore, Rosine Guimbaud, Matthieu Texier

J Clin Oncol· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Monocyte-lineage tumor infiltration predicts immunoradiotherapy response in advanced pretreated soft-tissue sarcoma: phase 2 trial results.
Antonin Levy, Daphné Morel, Matthieu Texier, Maria E Rodriguez-Ruiz, Lisa Bouarroudj

Signal Transduct Target Ther· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Sunitinib for the treatment of phaeochromocytomas and paragangliomas - Authors' reply.
Eric Baudin, Julien Hadoux, Alfredo Berruti, Livia Lamartina, Matthieu Texier

Lancet· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Theragnostic Gadolinium-Based Nanoparticles Safely Augment X-ray Radiation Effects in Patients with Cervical Cancer.
Cyrus Chargari, Pauline Maury, Matthieu Texier, Catherine Genestie, Philippe Morice

ACS Nano· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Sunitinib for metastatic progressive phaeochromocytomas and paragangliomas: results from FIRSTMAPPP, an academic, multicentre, international, randomised, placebo-controlled, double-blind, phase 2 trial.
Eric Baudin, Bernard Goichot, Alfredo Berruti, Julien Hadoux, Salma Moalla, Matthieu Texier

Lancet· March 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
An international phase II trial and immune profiling of SBRT and atezolizumab in advanced pretreated colorectal cancer.
Antonin Levy, Daphné Morel, Matthieu Texier, Roger Sun, Jerome Durand-Labrunie

Mol Cancer· March 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Olaparib maintenance versus placebo in platinum-sensitive non-small cell lung cancer: the Phase 2 randomized PIPSeN trial.
Sophie Postel-Vinay, Juan Coves, Matthieu Texier, Mihaela Aldea, Anas Gazzah

Br J Cancer· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Genomic Instability and Protumoral Inflammation Are Associated with Primary Resistance to Anti-PD-1 + Antiangiogenesis in Malignant Pleural Mesothelioma.
François-Xavier Danlos, Matthieu Texier, Bastien Job, Severine Mouraud, Lydie Cassard

Cancer Discov· April 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Plasma galectins and metabolites in advanced head and neck carcinomas: evidence of distinct immune characteristics linked to hypopharyngeal tumors.
Bao-Tram Thi Tran, Aurore Gelin, Sylvère Durand, Matthieu Texier, Amaury Daste

Oncoimmunology· December 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Analysis of the association between prospectively collected immune-related adverse events and survival in patients with solid tumor treated with immune-checkpoint blockers, taking into account immortal-time bias.
Maria Kfoury, Marie Najean, Ariane Lappara, Anne-Laure Voisin, Stéphane Champiat, Matthieu Texier

Cancer Treat Rev· November 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The GETUG SEMITEP Trial: De-escalating Chemotherapy in Good-prognosis Seminoma Based on Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography.
Yohann Loriot, Matthieu Texier, Stéphane Culine, Aude Fléchon, Antoine Thiery-Vuillemin

Eur Urol· August 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety, recommended dose, efficacy and immune correlates for nintedanib in combination with pembrolizumab in patients with advanced cancers.
Capucine Baldini, Francois-Xavier Danlos, Andreea Varga, Matthieu Texier, Heloise Halse

J Exp Clin Cancer Res· July 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
PD-1 iNhibitor and chemotherapy with concurrent IRradiation at VAried tumor sites in advanced Non-small cell lung cAncer: the Prospective Randomized Phase 3 NIRVANA-Lung Trial.
Jérôme Doyen, Benjamin Besse, Matthieu Texier, Naima Bonnet, Antonin Levy

Clin Lung Cancer· May 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Gefitinib plus tremelimumab combination in refractory non-small cell lung cancer patients harbouring EGFR mutations: The GEFTREM phase I trial.
Mariona Riudavets, Marie Naigeon, Matthieu Texier, Miriam Dorta, Fabrice Barlesi

Lung Cancer· April 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Late phase 1 studies: concepts and outcomes.
Jose Carlos Benitez, Arthur Geraud, Matthieu Texier, Christophe Massard, Angelo Paci

Lancet Oncol· October 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Intratumoral Immunotherapy: From Trial Design to Clinical Practice.
Stéphane Champiat, Lambros Tselikas, Siham Farhane, Thibault Raoult, Matthieu Texier

Clin Cancer Res· February 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Circulating T-cell Immunosenescence in Patients with Advanced Non-small Cell Lung Cancer Treated with Single-agent PD-1/PD-L1 Inhibitors or Platinum-based Chemotherapy.
Roberto Ferrara, Marie Naigeon, Edouard Auclin, Boris Duchemann, Lydie Cassard, Matthieu Texier

Clin Cancer Res· January 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparison of Fast-Progression, Hyperprogressive Disease, and Early Deaths in Advanced Non-Small-Cell Lung Cancer Treated With PD-1/PD-L1 Inhibitors or Chemotherapy.
Roberto Ferrara, Laura Mezquita, Matthieu Texier, Jihene Lahmar, Clarisse Audigier-Valette

JCO Precis Oncol· November 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Second-look surgery plus hyperthermic intraperitoneal chemotherapy versus surveillance in patients at high risk of developing colorectal peritoneal metastases (PROPHYLOCHIP-PRODIGE 15): a randomised, phase 3 study.
Diane Goéré, Olivier Glehen, François Quenet, Jean-Marc Guilloit, Jean-Marc Bereder, Matthieu Texier

Lancet Oncol· September 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical Relevance of EGFR- or KRAS-mutated Subclones in Patients With Advanced Non-small-cell Lung Cancer Receiving Erlotinib in a French Prospective Cohort (IFCT ERMETIC2 Cohort - Part 2).
Michèle Beau-Faller, Matthieu Texier, Hélène Blons, Nicolas Richard, Fabienne Escande

Clin Lung Cancer· May 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Hyperprogressive Disease in Patients With Advanced Non-Small Cell Lung Cancer Treated With PD-1/PD-L1 Inhibitors or With Single-Agent Chemotherapy.
Roberto Ferrara, Laura Mezquita, Matthieu Texier, Jihene Lahmar, Clarisse Audigier-Valette

JAMA Oncol· November 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evaluation of Treatment Effect with Paired Failure Times in a Single-Arm Phase II Trial in Oncology.
Matthieu Texier, Federico Rotolo, Michel Ducreux, Olivier Bouché, Jean-Pierre Pignon

Comput Math Methods Med· October 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Novel Spectroscopically Determined Pharmacodynamic Biomarker for Skin Toxicity in Cancer Patients Treated with Targeted Agents.
Antoine Azan, Peter J Caspers, Tom C Bakker Schut, Séverine Roy, Céline Boutros, Matthieu Texier

Cancer Res· January 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination.
Celine Boutros, Ahmad Tarhini, Emilie Routier, Olivier Lambotte, Francois Leroy Ladurie, Matthieu Texier

Nat Rev Clin Oncol· August 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis